The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy

Giorgio Ciprandi, Maria Angela Tosca, Michela Silvestri

Research output: Contribution to journalArticlepeer-review

Abstract

Allergic asthma and rhinitis are characterized by IgE-mediated inflammation consequent to the exposure to a specific allergen. Therefore, IgE production may be considered the hallmark of allergy. Actually, allergen immunotherapy (AIT) is the unique causal treatment for respiratory allergy. Indeed, successful AIT can induce a physiologic immune tolerance toward the causal allergen. There is evidence to show that AIT is safe and effective; its indication has been rigorously stated by robust position papers. AIT efficacy assessment is mainly based on symptom reduction and drug saving. AIT responder quote may range between 60 and 90% of AIT prescription. As AIT is expensive and long-lasting, the availability of a marker able to predict AIT responder is a crucial relevance. This issue has been the topic of several studies. Very recently, it has been preliminarly reported that a cut-off of serum specific IgE levels could define AIT-responder. However, further rigorous studies will confirm this view.

Original languageEnglish
Pages (from-to)321-324
Number of pages4
JournalExpert Review of Clinical Immunology
Volume10
Issue number3
DOIs
Publication statusPublished - Mar 2014

Keywords

  • allergen immunotherapy
  • allergen-specific IgE
  • allergic rhinitis
  • asthma
  • biomarker
  • responder
  • serum
  • total IgE

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy'. Together they form a unique fingerprint.

Cite this